Biogen (BIIB -1%) and Swedish partner Orphan Biovitrum say their Factor VIII Fc Fusion Protein...
Wednesday, October 31, 2012, 9:48 AM ETBiogen (BIIB -1%) and Swedish partner Orphan Biovitrum say their Factor VIII Fc Fusion Protein controlled bleeding in patients with Hemophilia A in a Phase III trial. Biogen now plans to file for FDA approval of the treatment in H1 next year and for EU authorization after it completes a study in children. The market for hemophilia A treatments is worth about $5B. (PR)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles